Figure 2.
Risk of mother-to-child transmission (infant HIV DNA positive at 4-6 weeks) among women receiving HAART before or during pregnancy compared to those receiving single-dose nevirapine or no maternal prophylaxis at the Charlotte Maxeke Johannesburg Academic Hospital and Rahima Moosa Mother and Child Hospital.
* all women receiving single dose nevirapine had CD4 counts ≥ 250 cells/mm3